Patent: 8,420,081
✉ Email this page to a colleague
Summary for Patent: 8,420,081
Title: | Antibody formulations and methods of making same |
Abstract: | The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductivity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality. |
Inventor(s): | Fraunhofer; Wolfgang (Shrewsbury, MA), Bartl; Annika (Ludwigshafen, DE), Krause; Hans-juergen (Grunstadt, DE), Tschoepe; Markus (Hessheim, DE), Kaleta; Katharina (Ludwigshafen, DE) |
Assignee: | AbbVie, Inc. (North Chicago, IL) |
Application Number: | 12/325,049 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,420,081 |
Patent Claims: | see list of patent claims |
Details for Patent 8,420,081
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Centocor Ortho Biotech Products, L.p. | ORTHOCLONE OKT3 | muromanab-cd3 | Injection | 103463 | September 14, 1992 | ⤷ Sign Up | 2027-11-30 |
Janssen Biotech, Inc. | REOPRO | abciximab | Injection | 103575 | December 22, 1994 | ⤷ Sign Up | 2027-11-30 |
Aytu Bioscience, Inc. | PROSTASCINT | capromab pendetide | Injection | 103608 | October 28, 1996 | ⤷ Sign Up | 2027-11-30 |
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | November 26, 1997 | ⤷ Sign Up | 2027-11-30 |
Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | February 19, 2002 | ⤷ Sign Up | 2027-11-30 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |